Recently, the topoisomerase I inhibitor Dxd-conjugated antibody against HER2 (DS-8201a) exhibited a superior antitumor activity in a broad selection of HER2-positive models, and it is suggested to be a valuable therapy with great potential to respond to T-DM1-insensitive HER2-positive cancers and low HER2-expressing cancers [28]. Here, ERBB2 is linked to cancer.